# Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: a cost-effectiveness analysis using a transmission model

David J Price, PhD<sup>1,2</sup>; Narimane Nekkab, PhD<sup>3,4</sup>; Wuelton M Monteiro, PhD<sup>5,6</sup>; Daniel AM Villela,

PhD7; Julie A. Simpson, PhD2; Marcus VG Lacerda, MD5,8; Michael T White, PhD9; Angela Devine,

## PhD<sup>2,10,11</sup>†

<sup>1</sup> Department of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute for

Infection and Immunity, Victoria, Australia

<sup>2</sup> Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia

University of Merodunic, Merodunic, Victoria, Australia

<sup>3</sup> Swiss Tropical and Public Health Institute, Basel, Switzerland

<sup>4</sup> University of Basel, Basel, Switzerland

<sup>5</sup> Instituto de Pesquisa Clínica Carlos Borborema, Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil

<sup>6</sup>Escola Superior de Ciências da Saúde, Universidade do Estado do Amazonas, Manaus, Brazil

<sup>7</sup> Programa de Computação Científica, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

<sup>8</sup> Instituto Leônidas & Maria Deane – ILMD, Fundação Oswaldo Cruz, Manaus, Brazil

<sup>9</sup> Institut Pasteur, Université de Paris, G5 Épidémiologie et Analyse des Maladies Infectieuses,

Département de Santé Globale, F-75015 Paris, France

<sup>10</sup> Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin

University, Darwin, Northern Territory, Australia

<sup>11</sup> Health Economics Unit, Centre for Health Policy, Melbourne School of Population and Global

Health, The University of Melbourne, Melbourne, Victoria, Australia

<sup>†</sup>Corresponding author: <u>angela.devine@menzies.edu.au</u>. 207 Bouverie St, Carlton, VIC 3053,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Australia

## 1 ABSTRACT

2 Background: Malaria transmission modelling has demonstrated the potential impact of semi-

- 3 quantitative glucose-6-phosphate dehydrogenase (G6PD) testing and treatment with single-dose
- 4 tafenoquine for *Plasmodium vivax* radical cure. This modelling has focused on predicting the number
- 5 of vivax cases averted, rather than its cost-effectiveness.
- 6 Methods: We explored the cost-effectiveness of using tafenoquine after G6PD screening as compared
- 7 to usual practice (7-day low-dose primaquine (0.5 mg/kg/day) without G6PD screening) in Brazil
- 8 using a 10-year time horizon with 5% discounting considering four scenarios: 1) tafenoquine for
- 9 adults only assuming 66.7% primaquine treatment adherence, 2) tafenoquine for adults and children
- aged >2 years assuming 66.7% primaquine adherence, 3) tafenoquine for adults only assuming 90%
- 11 primaquine adherence, 4) tafenoquine for adults only assuming 30% primaquine adherence. The
- 12 incremental cost-effectiveness ratios (ICERs) were estimated by dividing the incremental costs by the
- 13 disability-adjusted life-years (DALYs) averted. These were compared to a willingness to pay
- 14 threshold of US\$7,800 for Brazil, and one-way and probabilistic sensitivity analyses were performed.
- 15 **Results:** All four scenarios were cost-effective using this willingness to pay threshold with ICERs
- 16 ranging from US\$154–1836. One-way sensitivity analyses showed that the results were most sensitive
- 17 to severity and mortality due to vivax malaria, the lifetime and number of semi-quantitative G6PD
- analysers needed, cost per malaria episode and per G6PD test strips, and life expectancy. All
- 19 scenarios had a 100% likelihood of being cost-effective at the willingness to pay threshold.
- Conclusions: Tafenoquine prescribed after a semi-quantitative G6PD testing is highly likely to be
   cost-effective in Brazil.
- 22
- Keywords: malaria, vivax, cost-effectiveness, transmission model, glucose-6-phosphate
  dehydrogenase, screening
- 25

## 26 BACKGROUND

27 The burden of malaria in Brazil is primarily due to *Plasmodium vivax*, with an estimated 168,499 28 indigenous P. vivax cases reported in 2018[1, 2] contributing to an estimated national societal cost of 29 17.6 million United States Dollars (US\$) in 2017.[3] The control of vivax malaria is more challenging 30 than *P. falciparum* since the parasite forms hypnozoites, dormant liver parasites that can cause multiple 31 relapsing episodes of malaria and ongoing transmission. Current practice in Brazil is to prescribe radical 32 cure with a 3-day treatment of chloroquine for the blood-stage parasites and seven-day low-dose (3.5mg/kg total) primaguine to kill the liver-stage parasites. Full adherence to this regimen is suboptimal 33 34 in South America with studies estimating adherence ranging from 62% to 86%.[4-8] These estimates are likely to be elevated since observer bias results in an increase in a patient's likelihood to adhere to 35 36 a full course of treatment.[9]

37 Recent clinical trials have demonstrated that tafenoquine has comparable efficacy to low-dose 38 primaguine (total dose 3.5mg/kg) but has the advantage of being administered as a single dose.[10, 11] 39 Patients with vivax malaria who have glucose-6-phosphate-hydrogenase (G6PD) deficiency, an 40 inherited enzymopathy, are at risk of drug-induced haemolysis when taking either primaquine or 41 tafenoquine. The World Health Organization recommends screening for G6PD deficiency before 42 prescribing primaquine with a threshold for prescribing the drug set at 30% G6PD activity, a level amenable to qualitative diagnostics.[12] The threshold for G6PD deficiency for prescribing 43 44 tafenoquine, however, is set at 70%, which requires semi-quantitative screening. Current practice in 45 Brazil does not require screening for G6PD deficiency, but this has been associated with hospitalization 46 and mortality due to primaguine-induced haemolysis in patients with G6PD deficiency in Brazil.[13-15] Recently updated malaria guidelines in Brazil require G6PD screening before administering 47 primaguine at health facilities that have the capacity to provide G6PD testing.[16, 17] 48

The impact of tafenoquine following G6PD screening on transmission in Brazil has been explored in a recent mathematical model.[18] The model simulations demonstrated a decrease in transmission over a ten-year time horizon, although this was not sufficient to achieve elimination. Since a paediatric formulation of tafenoquine is being developed, a scenario is included to evaluate the impact of

prescribing to adults and children over the age of six months in addition to an adults only scenario. Here, we conduct a complementary economic evaluation with the transmission model predictions to explore the impact on the overall cost-effectiveness of a semi-quantitative G6PD test-and-treat strategy using tafenoquine for radical cure.

57

## 58 METHODS

59 Extending the analysis of 10 year projections of vivax malaria cases from a previously published 60 individual-based *P. vivax* transmission model for Brazil,[18] we conducted a cost-effectiveness analysis 61 to estimate the impact of tafenoquine following G6PD screening with a semi-quantitative test on costs and disability-adjusted life-years (DALYs). Full details of the transmission model can be found in 62 Nekkab et al.[18] Briefly, the P. vivax transmission model was calibrated using several data sources 63 64 from Brazil and validated by the National Malaria Control Programme and malaria experts in Brazil. The results cover a ten-year time horizon from 2020 to 2029 and assume that G6PD screening is fully 65 66 rolled out in January 2021. The economic evaluation model was coupled with the transmission model, using its projected outcomes to calculate the costs and DALYs averted. For each municipality and year, 67 68 the number of primaguine and tafenoquine doses, cases in males and females over 16 years, cases in males and females under 16 years, number of cases in pregnant women, and G6PD tests were provided 69 70 by the transmission model. The model assumed a truncated exponential age distribution with a mean age of 32 years. Under this model 15.6% of those under 16 years would be under the age of 2 years and 71 72 therefore be ineligible for tafenoquine. Approximately 4% of those under 16 years would be under the age of 6 months and not receive radical cure, while the remainder of children under 2 years would 73 74 receive primaquine.

The analysis explored four treatment policy scenarios for tafenoquine following G6PD screening from the transmission model[18]; each of which were compared to the baseline scenario of seven-day lowdose primaquine (3.5mg/kg total) for all eligible patients without G6PD screening. Screening for G6PD deficiency was done via semi-quantitative testing, repeated at each presentation with malaria. Scenario 1 explored tafenoquine for adults over the age of 16 (tafenoquine for adults), while Scenario 2 expanded

access to children who were over the age of 2 years (tafenoquine for all). While Scenarios 1 and 2 assumed that adherence to the seven-day primaquine regimen was 66.7%,[8] Scenarios 3 (high primaquine adherence) and 4 (low primaquine adherence) explored the impact of assuming 90% and 30% pre-existing primaquine adherence when prescribing tafenoquine to adults, respectively. The baseline adherence rate estimate of 66.7% was chosen from a study that appeared to best reflect the current situation in Brazil.[8] The values of 30% and 90% in Scenarios 3 and 4 were selected to be extreme for the purposes of the sensitivity analyses for the transmission model.[18]

87 In all scenarios, children over the age of two years received a G6PD test before being prescribed radical 88 cure. Cases amongst children were assumed to be proportionally distributed; that is, we assumed that 4% of cases in children under 16 years occurred in children under the age of six months, and allocated 89 90 these cases accordingly as excluded from radical cure. Pregnant and lactating women were not eligible for radical cure, so these women were not tested for G6PD deficiency or assigned any costs for radical 91 92 cure. Pregnancy resulted in a nine-month exclusion from radical cure, and a further six months were excluded for breastfeeding. The total number of G6PD tests in a given municipality and year were 93 94 divided proportionally in those who were eligible for radical cure by cases in males and females over 95 16 years and cases in males and females under 16 years.

G6PD deficiency varied by province and G6PD activity score distribution was based on Markov chain
Monte Carlo fitted Gaussian mixture models to four datasets.[18] For two states in which survey data
were not available a national-level prevalence of 5.52% G6PD deficiency was used. The diagnostic
accuracy of the test was taken from a study in Brazil that was used to inform the US FDA submission
for the SD Biosensor STANDARD G6PD Test (Table 1).[19] Parameters relating to risk of severe
malaria, haemolysis, and mortality are provided in Table 1.

- 103
- 104
- 105

106 Table 1. Unit costs in 2020 United States dollars (US\$), diagnostic accuracy of G6PD screening, and risk of107 haemolysis, severe malaria and death.

Parameter	Base parameter value (low – high)	Source	Notes
Cost of clinical malaria visit	17 (9 – 26)	[20] ±50%	
Cost of hospitalization for severe malaria	59 (51 - 66)	[21]	
Cost of hospitalization for haemolytic event	87 (49 – 124)	[21]	
Cost of primaquine treatment	0.43 (0.35 – 0.52)	Assumption ±20%	From Ministry of Health
Cost of tafenoquine treatment	1.78 (1.42 – 2.09)	[22]	
Cost of semi-quantitative test machine	619 (375 – 688)	Assumption	From test distributor
Cost of semi-quantitative test strip	6.8 (4.1 – 8.2)	Assumption	From test distributor. (Assumes no wastage)
Cost of monthly quality assurance	20 (17 – 23)	Assumption	Cost of controls from test distributor. Cost is divided by the number of patients per month.
Cost for annual healthcare worker training	58 (29 – 87)	Local data ±20%	Assumed two healthcare workers per healthcare facility
Cost per blood draw	0.64 (0.32 – 0.96)	Local data ±50%	Additional blood draw is needed per person screened for glucose-6- phosphate- dehydrogenase deficiency
Sensitivity for severe G6PD deficiency (<30%)	0.999 (0.94 – 1.00)	[19]	
True intermediates that are misclassified as <30% activity (no radical cure)	0.49 (0.39 – 0.58)	[19] ±20%	
True intermediates that are misclassified as $\geq$ 70% activity (prescribed tafenoquine)	0.06 (0.05 – 0.07)	[19] ±20%	
Specificity for $\geq 70\%$ activity	0.95 (0.90 - 1.00)	[19]	
Risk of haemolysis if severe G6PD deficient and given radical cure	0.038 (0.015 – 0.061)	[14]	
Risk of haemolysis if intermediate G6PD deficient and given radical cure	0.031 (0.001 – 0.038)	Assumption	
Mortality due to radical cure- induced haemolysis	0.011 (0.005 – 0.016)	[14]	
Probability of severe malaria requiring hospitalization	0.03 (0.015 - 0.045)	[13]	
Probability of mortality due to vivax malaria	0.0003 (0 - 0.0005)	[13]	

108 G6PD = glucose-6-phosphate-dehydrogenase

## 109 <u>Costs</u>

Costs are reported in 2020 US\$. When applicable, costs were inflated to 2020 using gross domestic 110 111 product deflators[23] and converted from BRL to US\$.[24] Table 1 provides the unit costs and further 112 information about how these costs were applied. The cost of radical cure was also included for severe 113 cases, but it was assumed this would be prescribed after release from the hospital. The semi-quantitative 114 machine was assumed to have a lifetime of five years (range: 3 to 10). The number of healthcare facilities in each municipality was calculated from the 2018 Malaria Epidemiological Surveillance 115 Information System (SIVEP) data on number of health units that saw at least 100 cases of vivax 116 malaria.[2, 21] In the base case, it was assumed that on average 1.05 machines (range: 1 to 2) would 117 be needed per healthcare facility. 118

#### 119 <u>DALYs</u>

DALYs for each scenario were calculated by adding the years of life lost to the years of life with disability. Model parameters for years of life with disability are shown in Appendix 1. It was assumed that all malaria cases resulted in anaemia. The average age of patients with vivax malaria by sex were derived from the SIVEP database.[21] These ages matched to the life expectancy for that age and sex to calculate the years of life lost.[25] Life expectancy for both sexes was varied by  $\pm 10\%$  in the sensitivity analyses.

#### 126 <u>Analyses</u>

Both costs and outcomes were discounted at 5% per year in the base case analysis to reflect the value 127 128 that society attaches to present consumption as opposed to consumption in the future in Brazil. In 129 addition, results are also presented for 0% and 10% discounting. Total costs and DALYs were calculated 130 for each scenario as compared to the baseline scenario. The incremental cost-effectiveness ratio (ICER) 131 was calculated by dividing the difference in costs by the number of DALYs averted. The base case 132 analysis was run for each of 124 municipalities in Brazil that reported at least 100 vivax malaria cases 133 to SIVEP during 2018. Two municipalities representing low-transmission settings were excluded from 134 the analysis (Ji-Paraná, and Paragominas) on the basis that stochastic variability and fadeout dominated the low numbers of cases in the transmission model simulations. These results were mapped to show 135

variation between municipalities; and the overall ICER is presented as the national cost divided by the
national DALYs averted. A willingness to pay (WTP) threshold of US\$7,800 (40,000 BRL) was used.
This is the threshold set by the National Commission for the Incorporation of Technologies (CONITEC)
and represents the maximum value that an intervention should cost per DALY averted to be considered
cost-effective.[26] CONITEC is the health technology assessment agency for the Brazilian Unified
Health System.

142 A one-way sensitivity analysis and probabilistic sensitivity analysis (PSA) was run on all parameters in the cost-effectiveness analyses. For the PSA, gamma distributions were used for costs and DALY 143 144 weights, and beta distributions were used for all other parameters except for the lifetime of the semiquantitative machine. For this parameter we assumed a normal distribution truncated below at 1 year, 145 on the assumption that the average semi-quantitative device lifetime was at least 1 year. A range of two 146 to ten years was used for the lifetime of the semi-quantitative machine in the one-way sensitivity 147 148 analysis. A total of 10,000 model parameters were sampled from the specified distributions. The PSA model parameters were applied to each municipality for the four scenarios, enabling the overall mean 149 150 costs, DALYs, and ICERs to be calculated and the 2.5 and 97.5 percentiles (referred to herein as the 151 95% Credible Interval [95%CrI]).

152 To provide insights into a range of epidemiological transmission settings, the results of the sensitivity 153 analyses are presented for three municipalities: peri-urban Manaus, São Gabriel da Cachoeira, and 154 Itaituba. The first two municipalities are in the state of Amazonas, while Itaituba is in Pará state. Periurban Manaus excludes the malaria-free urban areas of that municipality. While peri-domestic 155 156 transmission drove cases in São Gabriel da Cachoeira, occupational exposure in working-aged males 157 was the primary cause of cases in Itaituba municipality. Transmission intensity was 23 cases per 1000 person years in Itaituba, 112/1000 in peri-urban Manaus, and 267/1000 in São Gabriel da 158 159 Cachoeira.[18]

160

## 161 **RESULTS**

## 162 <u>Base case analysis</u>

- 163 The baseline results for *P. vivax* malaria treatment in Brazil with 5% discounting were consistently cost-
- 164 effective using a WTP threshold of US\$7,800 (Table 2). The ICER for Scenario 1 (tafenoquine for
- adults) was US\$982, dropping to US\$472 when children testing G6PD normal were prescribed
- tafenoquine (Scenario 2). With an ICER of US\$154, Scenario 4 (low primaguine adherence) was the
- 167 most cost-effective scenario. The smallest health gains were estimated for Scenario 3 (high primaquine
- adherence); however, the ICER of US\$1,836 for this scenario was still below the WTP threshold. The
- results without discounting and with a discount rate of 10% are also provided in Table 2.
- 170 Figure 1 shows the map of ICERs by municipality. The ICER for São Gabriel da Cachoeira was
- 171 US\$2,145 for Scenario 1 and US\$679 for Scenario 2; and the corresponding ICERs were US\$1,322 and
- 172 US\$556 in peri-urban Manaus. In Itaituba, where occupational exposure in working-aged males drives
- transmission, the ICER increased to US\$558 in Scenario 2 where children > 2 years were prescribed
- tafenoquine, as compared to the ICER of US\$458 for Scenario 1.
- 175

Scenario	Cases	Cases averted	Costs	Incremental costs	DALYs	DALYs averted	ICER
Costs and DALYs discounted at 5%							
Baseline*	2,106,083	-	32,576,457	-	42,289	-	-
1 (tafenoquine for adults) †	1,731,540	374,543	42,036,795	9,460,338	32,656	9,632	982
2 (tafenoquine for all) †	1,548,669	557,414	38,707,666	6,131,209	29,269	13,020	472
3 (high primaquine adherence) ‡	1,891,021	215,062	45,267,047	12,690,589	35,376	6,912	1,836
4 (low primaquine adherence) §	1,388,891	717,192	34,985,479	2,409,021	26,651	15,638	154
Undiscounted costs and DALYs		·					
Baseline*	2,106,083	-	40,141,225	-	52,111	-	-
1 (tafenoquine for adults) †	1,731,540	374,543	51,626,032	11484807	39829	12281	935
2 (tafenoquine for all) †	1,548,669	557,414	47,382,476	7241251	35518	16592	436
3 (high primaquine adherence) ‡	1,891,021	215,062	55,935,828	15794603	43467	8644	1827
4 (low primaquine adherence) §	1,388,891	717,192	42,529,751	2388526	32084	20027	119
Costs and DALYs discounted at	10%						
Baseline*	2,106,083	-	27179528	-	35282	-	-
1 (tafenoquine for adults) †	1,731,540	374,543	35170590	7991062	27517	7765	1029
2 (tafenoquine for all) †	1,548,669	557,414	32493300	5313772	24788	10494	506
3 (high primaquine adherence) ‡	1,891,021	215,062	37646705	10467177	29596	5686	1841
4 (low primaquine adherence) §	1,388,891	717,192	29564278	2384750	22740	12541	190

177 **Table 2.** Total overall cases, costs, disability-adjusted life-years (DALYs), and incremental cost-effectiveness ratios (ICERs) for Brazil from 2020–2029.

178 \*7-day low dose primaquine (0.5 mg/kg), primaquine adherence set at comparison scenario. † Primaquine adherence = 66.7%. ‡ Primaquine adherence = 90%.

179 § Primaquine adherence = 30%.



Figure 1. Map of incremental cost-effectiveness ratios (ICERs) in each malaria-endemic municipality 181 for Scenario 1 (tafenoquine for adults, primaguine adherence 66.7%), Scenario 2 (tafenoquine for all, 182 primaguine adherence 66.7%), Scenario 3 (tafenoquine for adults, high primaguine adherence of 90%), 183 and Scenario 4 (tafenoquine for adults, low primaguine adherence of 30%), compared to baseline (7 184 day low-dose primaquine (0.5 mg/kg), adherence set at comparison scenario). The municipality of 185 Manaus is plotted using results for peri-urban Manaus. The ICER for the municipality of Caapiranga 186 for Scenario 3 was US\$60,273, well above the scale. Municipalities where a strategy increased DALYs 187 188 as compared to baseline are shown in grey.

189

## 190 <u>One-way sensitivity analysis</u>

Figure 2 shows the ten parameter values that have the largest impact on the ICER for Scenarios 1 191 192 (tafenoquine for adults) and 2 (tafenoquine for all) in the three municipalities. The parameters with the 193 largest impact on results across all municipalities were the severity and mortality due to vivax malaria, 194 life expectancy, the lifetime and number of semi-quantitative G6PD machines needed, and the costs of 195 G6PD test strips and malaria episodes. These results also reflected transmission intensity of the 196 municipalities. For example, Itaituba had the lowest transmission intensity so the lifetime of the semi-197 quantitative machine, which impacts the cost per person screened, resulted in the highest impact on the 198 ICER. The magnitude of the impact for Itaituba was not as large as São Gabriel da Cachoeira, which 199 had the highest transmission intensity and for peri-urban Manaus, a moderate transmission setting. 200 Reflecting the potential impact of tafenoquine depending on current primaquine adherence levels, the 201 one-way sensitivity analyses in Scenario 3 (high primaquine adherence) showed a much larger impact 202 on the results while the impact was markedly smaller in Scenario 4 (low primaguine adherence; Appendix 2). Scenario 3 (high primaquine adherence) was not cost-effective across all three 203 municipalities. 204

205 Since occupational exposure amongst working-aged males drives transmission in Itaituba, the 206 parameters with the largest impact on the results were consistent across Scenarios 1 & 2. In the other 207 two municipalities where children bore more of the vivax malaria burden, the parameters with the 208 largest impact switched around more when children were prescribed tafenoquine in Scenario 2. For 209 Scenario 3 (high primaquine adherence), the 10% increase in life expectancy from the base case to the high value resulted in an additional 4 years for males and 5 years for females in peri-urban Manaus 210 211 while it was 6 years for males and 5 years for females in São Gabriel da Cachoeira. This had a substantial impact on the cost-effectiveness results, causing the ICER to rise beyond the WTP threshold in both 212 municipalities (US\$12,373 and US\$22,467, respectively). This was driven by mortality having a larger 213 214 impact on overall DALYs averted than morbidity and by high pre-existing primaquine adherence

# 215 decreasing the benefits in terms of relapses (and therefore deaths due to vivax malaria) due to

# 216 prescribing tafenoquine.



217



223

## 224 <u>Probabilistic Sensitivity Analysis</u>

Appendix 3 shows the cost-effectiveness planes produced by the PSA results. All model iterations at

the country level were in the east quadrants, indicating that the tafenoquine scenarios would result in

227 fewer DALYs than current practice. The mean ICER for Scenario 1 (tafenoquine for adults) was US\$1011 (95%CrI US\$480 to US\$1837) compared to US\$982 in the base case analysis, US\$483 228 (95%CrI US\$69 to US\$1052) compared to US\$471 for Scenario 2 (tafenoquine for all), and US\$1,954 229 (95%CrI US\$1104 to US\$3,272) for Scenario 3 (high primaquine adherence) compared to US\$1,836. 230 231 Conversely, Scenario 4 (low primaquine adherence) had decreased incremental costs while DALYs averted increased as compared to the base case analysis. While all scenarios showed higher incremental 232 costs and DALYs averted than the base case, only Scenario 4 had a lower mean ICER with US\$146 233 234 (95%CrI -US\$255 to US\$589) as compared to the base case (US\$154). The cost-effectiveness 235 acceptability curves in Figure 3 summarize these model iterations, by showing the percentage that fall below WTP thresholds ranging from US\$0 to US\$10,000. For all scenarios, 100% of model iterations 236 237 were cost-effective at a WTP threshold of US\$7,800. The results for the selected municipalities were 238 similar to those at the country level, with nearly all model iterations (>99%) averting DALYs and some 239 indicating cost savings (Appendix 5). Again, the CEACs for the municipalities showed a high likelihood 240 of being cost-effective (Appendix 6). These results were consistent across the different transmission 241 intensities of the selected municipalities.

242

243

244

245



Figure 3. Cost-effectiveness acceptability curves overall in Brazil for Scenario 1 (tafenoquine for adults, primaquine adherence 66.7%), Scenario 2 (tafenoquine for all, primaquine adherence 66.7%),
Scenario 3 (tafenoquine for adults, high primaquine adherence of 90%), and Scenario 4 (tafenoquine for adults, low primaquine adherence of 30%), compared to baseline (7 day low-dose primaquine (0.5 mg/kg), adherence set at comparison scenario). The black vertical line represents the willingness-to-pay threshold (USD\$7,800).

254

247

## 255 DISCUSSION

Our results provide robust evidence that the use of tafenoquine after semi-quantitative G6PD testing would be cost-effective at a WTP threshold of US\$7,800, particularly in scenarios where children could be treated with a paediatric formulation or where adherence to primaquine is low. To our knowledge, this is the first cost-effectiveness analysis of tafenoquine utilizing a transmission model for *P. vivax*. This analysis benefits from the robust database in Brazil (SIVEP)[21] and recent cost data collection that has occurred alongside ongoing studies in Brazil.

Despite having a large impact on its effectiveness, adherence to primaquine is challenging to estimate.[27] Unsurprisingly, adherence to primaquine had a large impact on the cost-effectiveness with the largest ICER seen for Scenario 3 (90% pre-existing primaquine adherence), since single-dose tafenoquine would provide only an additional 10% improvement to adherence for radical cure in this

266 scenario. It is reassuring that this ICER of US\$1,836 in Scenario 3 was still well below the US\$7,800 267 WTP threshold for Brazil. A recent multi-component intervention in Brazil resulted in similar levels of 268 adherence; however, this level of adherence required increased investment in education, text message reminders to take primaquine, and follow-up phone surveys.[28] When assuming 30% pre-existing 269 270 primaquine adherence in Scenario 4, the ICER for the tafenoquine strategy had the smallest ICER 271 (US\$154), indicating improvements in health outcomes for a very small investment. While Brazil guidelines currently recommend a seven-day low-dose primaquine regimen (total dose 3.5 mg/kg), 272 273 many countries continue to use the 14-day low-dose regimen (total dose 3.5 mg/kg) recommended by 274 WHO,[12] which may result in lower adherence rates than used in the base case analysis. While 275 primaquine efficacy is high when adherence is good, our results demonstrate the potential for 276 tafenoquine to save costs in settings where adherence to primaquine is low (30%).

The one-way sensitivity analysis on three municipalities with diverse epidemiology revealed that the 277 278 results were least impacted by changes to parameter values in Itaituba, which had the lowest 279 transmission intensity of the three municipalities examined. This is in line with the transmission model 280 impact results, which indicated that the highest proportional drop in transmission would be in the 281 moderate-to-low transmission settings.[18] The parameters with the largest impact on the cost-282 effectiveness results across all municipalities were the lifetime and number of semi-quantitative G6PD 283 machines needed, severity and mortality due to vivax malaria, cost of G6PD test strips, and life 284 expectancy. The lifetime of the semi-quantitative G6PD machine before it needs to be replaced and 285 number of machines needed per facility impact the total cost per person screened, so this was expected, 286 particularly for settings with low transmission intensity like Itaituba.

A limitation of our study is regarding the uncertainty of our cost estimates for low transmission settings due to higher stochasticity of the transmission model and model assumptions. For very low transmission settings, stochastic noise and fadeout result in more unstable transmission dynamics and greater variation between simulations. In addition, calibrated incidence per 1000 population for these low transmission settings assumes homogenous mixing in the population and no importations to sustain transmission; therefore, local transmission dynamics in communities are likely to differ compared to

the simplified model aggregated municipality-level assumptions. Consequently, projected DALYs for these settings are less reliable and should be interpreted with caution. However, by estimating costs for a large range of transmission settings across Brazil and providing detailed results for three archetype settings with stable transmission, the drivers of impact on costs we identified overall are less impacted by model uncertainty.

Appropriately incorporating the costs of semi-quantitative G6PD screening is challenging for a number 298 299 of reasons. First, the costs of the machine, test strips, and controls have not been confirmed for 300 procurement by the Ministry of Health in Brazil. While we have indicative costs, these may change due 301 to distribution costs, customs, taxes, and any price changes that may occur when negotiating purchase of enough machines to implement nationally in Brazil. Second, the model assumed that G6PD screening 302 can begin everywhere at the same time. It is likely that the roll out will occur gradually and that uptake 303 304 may be slow or patchy. In addition, it is assumed that a semi-quantitative machine will be placed at 305 health units that had a case of vivax malaria in 2018 throughout the entire time horizon of the analysis. For large units and units that make home visits, more than one machine might be needed; this would 306 307 increase the costs. Alternatively, health units that do not continue to see malaria cases may not need to 308 continue stocking a semi-quantitative machine. Finally, since transmission is an important driver of 309 results, these findings are dependent on future trends in vivax malaria cases.

310 Severity and mortality of vivax malaria are also challenging parameters to estimate as data are sparse. 311 The base case value of 0.03% used here was from a study of vivax malaria patients admitted to a hospital in Brazil during 2009–11[13] and from a review that accessed 2014 data on microscopically confirmed 312 313 malaria cases and related deaths from the National Malaria Prevention and Control Programme, 314 Ministry of Health of Brazil.[29] The latter included falciparum malaria, indicating that it may be an 315 overestimate. Another study of vivax malaria from a tertiary care centre in Manaus from 1996 to 2010 found a lower case fatality rate of 0.01%.[15] To be conservative, our low value for the sensitivity 316 317 analyses assumed no mortality due to vivax malaria. While this parameter had a large impact on the 318 results in the one-way sensitivity analysis, all scenarios remained cost-effective across all three 319 municipalities when this assumption was applied.

Finally, this only compares tafenoquine with low-dose primaquine treatment. While low-dose primaquine (3.5 mg/kg total) is the current recommended treatment in Brazil, a recent comparison of low-dose with a high-dose primaquine regimen (7.0 mg/kg total) found a 27% difference in the percentage of patients who were recurrence-free at day 168 when these regimens were supervised.[30] While tafenoquine has been shown to have similar efficacy to low-dose primaquine,[10] it has not been directly compared to high-dose primaquine in Brazil. This clinical comparison would need to be done before the implications for the cost-effectiveness analysis could be ascertained.

327

## 328 CONCLUSIONS

Our cost-effectiveness analysis using a transmission model calibrated to epidemiological data from Brazil demonstrates a high probability of tafenoquine to be cost-effective at a threshold of US\$7,800 per DALY averted, following a normal test result with a semi-quantitative G6PD test. This intervention is most likely to be cost-effective in situations where primaquine adherence is low and when paediatric formulations enable it to be prescribed to children over the age of six months.

334

## 335 LIST OF ABBREVIATIONS

336 DALY = disability-adjusted life-years

- 337 G6PD = glucose-6-phosphate dehydrogenase
- 338 ICER = incremental cost-effectiveness ratio
- 339 SIVEP = Malaria Epidemiological Surveillance Information System
- 340 US\$ = United States Dollars
- 341 WTP = willingness to pay

342

## 343 DECLARATIONS

- 344 Ethics approval and consent to participate
- 345 Not applicable.

347	Consent for publication			
348	Not applicable.			
349				
350	Availability of data and materials			
351	The transmission model code is available at <u>https://github.com/MWhite-</u>			
352	InstitutPasteur/Pvivax_TQ_IBM. Parameters for the economic analyses are described in the manuscript			
353	and supplementary materials.			
354				
355	Competing interests			
356	The authors declare that they have no competing interests.			
357				
358	Funding			
359	This work was supported by Medicines for Malaria Ventures. WMM is funded by FAPEAM through			
360	POSGRAD and Pró-Estado public calls. WMM and ML are fellows of the National Council for			
361	Scientific and Technological Development (CNPq). MTW is funded by The Bill & Melinda Gates			
362	Foundation [grant number INV-024368]. The funding bodies did not have a role in the design of the			
363	study and collection, analysis, and interpretation of data and in writing.			
364				
365	Authors' contributions			
366	DJP developed the methods, performed the analysis, and wrote the first draft of the manuscript. NN			
367	conceptualized the study, developed the methods, and performed the analysis. WMM curated the data			
368	and developed the methods. DAMV curated the data and developed the methods. JAS supervised and			
369	interpreted the data. MVGL developed the methods and supervised the research. MTW			
370	conceptualized and supervised the study and developed the methods. AD conceptualized the study,			
371	acquired the funding, performed the analysis, developed the methods, supervised the research, and			
372	wrote the first draft of the manuscript. All authors read and approved the final manuscript.			

## 374 Acknowledgements

- 375 Not applicable.
- 376

# **377 REFERENCES**

- 378 1. World Health Organization. World malaria report 2019. Geneva: 2019.
- 2. Lana R, Nekkab N, Siqueira AM, Peterka C, Marchesini P, Lacerda M, et al. The top 1%:
- quantifying the unequal distribution of malaria in Brazil. Malaria Journal. 2021;20(1):87. doi:
- **381** 10.1186/s12936-021-03614-4.

382 3. Devine A, Battle KE, Meagher N, Howes RE, Dini S, Gething PW, et al. Global economic

383 costs due to vivax malaria and the potential impact of its radical cure: A modelling study. PLOS

384 Medicine. 2021;18(6):e1003614. doi: 10.1371/journal.pmed.1003614.

4. Grietens KP, Soto V, Erhart A, Ribera JM, Toomer E, Tenorio A, et al. Adherence to 7-day

primaquine treatment for the radical cure of *P. vivax* in the Peruvian Amazon. Am J Trop Med Hyg.

387 2010;82(6):1017-23. Epub 2010/06/04. doi: 10.4269/ajtmh.2010.09-0521. PubMed PMID: 20519594;

388 PubMed Central PMCID: PMCPMC2877405.

5. Duarte EC, Pang LW, Ribeiro LC, Fontes CJ. Association of subtherapeutic dosages of a
standard drug regimen with failures in preventing relapses of vivax malaria. The American journal of
tropical medicine and hygiene. 2001;65(5):471-6. doi: 10.4269/ajtmh.2001.65.471. PubMed PMID:
11716100.

Buarte EC, Gyorkos TW. Self-reported compliance with last malaria treatment and
occurrence of malaria during follow-up in a Brazilian Amazon population. Tropical medicine &
international health : TM & IH. 2003;8(6):518-24. doi: 10.1046/j.1365-3156.2003.01042.x. PubMed
PMID: 12791057.

Pereira EA, Ishikawa EAY, Fontes CJF. Adherence to *Plasmodium vivax* malaria treatment in
the Brazilian Amazon Region. Malaria journal. 2011;10:355-. doi: 10.1186/1475-2875-10-355.
PubMed PMID: 22165853.

Almeida ED, Rodrigues LCS, Vieira JLF. Estimates of adherence to treatment of vivax
malaria. Malaria journal. 2014;13:321-. doi: 10.1186/1475-2875-13-321. PubMed PMID: 25127886.

402	9. Bruxvoort K, Goodman C, Kachur SP, Schellenberg D. How patients take malaria treatment:
403	a systematic review of the literature on adherence to antimalarial drugs. PLoS One. 2014;9(1):e84555
404	Epub 2014/01/28. doi: 10.1371/journal.pone.0084555. PubMed PMID: 24465418; PubMed Central
405	PMCID: PMCPMC3896377.
406	10. Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, et al.
407	Single-Dose Tafenoquine to Prevent Relapse of <i>Plasmodium vivax</i> Malaria. N Engl J Med.
408	2019;380(3):215-28. Epub 2019/01/17. doi: 10.1056/NEJMoa1710775. PubMed PMID: 30650322.

409 11. Llanos-Cuentas A, Lacerda MVG, Hien TT, Velez ID, Namaik-Larp C, Chu CS, et al.

410 Tafenoquine versus Primaquine to Prevent Relapse of *Plasmodium vivax* Malaria. N Engl J Med.

411 2019;380(3):229-41. Epub 2019/01/17. doi: 10.1056/NEJMoa1802537. PubMed PMID: 30650326.

- 412 12. World Health Organisation. Guidelines for the Treatment of Malaria. Geneva, Switzerland:413 2015.
- 414 13. Siqueira AM, Lacerda MVG, Magalhães BML, Mourão MPG, Melo GC, Alexandre MAA, et

al. Characterization of *Plasmodium vivax*-associated admissions to reference hospitals in Brazil and

416 India. BMC medicine. 2015;13:57-. doi: 10.1186/s12916-015-0302-y. PubMed PMID: 25889040.

417 14. Brito-Sousa JD, Santos TC, Avalos S, Fontecha G, Melo GC, Val F, et al. Clinical Spectrum

418 of Primaquine-induced Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficiency: A 9-Year

419 Hospitalization-based Study From the Brazilian Amazon. Clin Infect Dis. 2019;69(8):1440-2. Epub

420 2019/02/13. doi: 10.1093/cid/ciz122. PubMed PMID: 30753364.

421 15. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhães BM, Siqueira AM, et al.

422 Postmortem characterization of patients with clinical diagnosis of Plasmodium vivax malaria: to what

423 extent does this parasite kill? Clin Infect Dis. 2012;55(8):e67-74. Epub 2012/07/10. doi:

424 10.1093/cid/cis615. PubMed PMID: 22772803.

425 16. Zobrist S, Brito M, Garbin E, Monteiro WM, Clementino Freitas S, Macedo M, et al.

426 Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in

- 427 Brazil. PLOS Neglected Tropical Diseases. 2021;15(8):e0009649. doi: 10.1371/journal.pntd.0009649.
- 428 17. Ministerio da Saude. Guia de tratamento da malaria no Brazil. Versao preliminar. 2019.

- 429 18. Nekkab N, Lana R, Lacerda M, Obadia T, Siqueira A, Monteiro W, et al. Estimated impact of
- 430 tafenoquine for Plasmodium vivax control and elimination in Brazil: A modelling study. PLoS Med.
- 431 2021;18(4):e1003535. Epub 2021/04/24. doi: 10.1371/journal.pmed.1003535. PubMed PMID:
- **432 33891582**.
- 433 19. Evaluation of a point-of-care test for G6PD deficiency in Brazil: The SD Biosensor
- 434 STANDARD G6PD Test. 2020 October 2020. Report No.
- 435 20. Peixoto HM, Brito MA, Romero GA, Monteiro WM, de Lacerda MV, de Oliveira MR. G6PD
- 436 deficiency in male individuals infected by *Plasmodium vivax* malaria in the Brazilian Amazon: a cost
- 437 study. Malar J. 2015;14:126. Epub 2015/04/19. doi: 10.1186/s12936-015-0647-x. PubMed PMID:
- 438 25889063; PubMed Central PMCID: PMCPMC4381355.
- 439 21. Brazil Ministry of Health. SIVEP-MALARIA—Sistema de informação de vigilancia
- 440 epidemiologica—notificacao de casos. Brasılia Brazil Ministry of Health; 2021.
- 441 22. GSK P. Assessing innovative models for the cost-effective distribution of *P. vivax* Malaria
  442 commodities. 2021.
- 443 23. The World Bank. GDP deflator (base year varies by country): The World Bank;; 2019 [cited
- 444 2020 10 Nov]. Available from: https://data.worldbank.org/indicator/NY.GDP.DEFL.ZS
- 445
- 446 24. The World Bank. Official exchange rate (LCU per US\$, period average) 2019 [cited 2020 10
- 447 Nov]. Available from: <u>https://data.worldbank.org/indicator/PA.NUS.FCRF</u>.
- 448 25. World Health Organization. Life tables by country: Global Health Observatory data
- 449 repository
- 450 2020
- 451 [updated 2020-12-06; cited 2021 30 April]. Available from:
- 452 <u>http://apps.who.int/gho/data/node.main.LIFECOUNTRY?lang=en</u>.
- 453 26. Ministério da Saúde. Uso de limiares de custo-efetividade nas decisões em saúde:
- 454 recomendações da Comissão Nacional de Incorporação de Tecnologias no SUS. Brasília, DF.

- 455 https://www.gov.br/conitec/pt-br/midias/pdf/2022/20221106 relatorio-uso-de-limiares-de-custo-
- 456 <u>efetividade-nas-decisoes-em-saude.pdf</u> 2022.
- 457 27. Thriemer K, Bobogare A, Ley B, Gudo CS, Alam MS, Anstey NM, et al. Quantifying
- 458 primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax
- 459 Working Group. Malar J. 2018;17(1):241. Epub 2018/06/22. doi: 10.1186/s12936-018-2380-8.
- 460 PubMed PMID: 29925430; PubMed Central PMCID: PMCPMC6011582.
- 461 28. Macías Saint-Gerons D, Rodovalho S, Barros Dias ÁL, Lacerda Ulysses de Carvalho A,
- 462 Beratarrechea A, Monteiro WM, et al. Strengthening therapeutic adherence and pharmacovigilance to
- 463 antimalarial treatment in Manaus, Brazil: a multicomponent strategy using mHealth. Malaria Journal.
- 464 2022;21(1):28. doi: 10.1186/s12936-022-04047-3.
- 465 29. Ferreira MU, Castro MC. Challenges for malaria elimination in Brazil. Malar J.
- 466 2016;15(1):284. Epub 2016/05/22. doi: 10.1186/s12936-016-1335-1. PubMed PMID: 27206924;
- 467 PubMed Central PMCID: PMCPMC4875681.
- 468 30. Chamma-Siqueira NN, Negreiros SC, Ballard SB, Farias S, Silva SP, Chenet SM, et al.
- 469 Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med.
- 470 2022;386(13):1244-53. doi: 10.1056/NEJMoa2104226. PubMed PMID: 35353962.
- 471 31. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and
- 472 national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195
- 473 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease
- 474 Study 2017. The Lancet. 2018;392(10159):1789-858. doi: 10.1016/S0140-6736(18)32279-7.
- 475
- 476
- 477
- 478
- 479
- 480

# 481 APPENDIX

# 482 Appendix 1. Model parameters for the disability-adjusted life-years and sources.

	Parameter	Base parameter value (low – high)	Sources and notes
	Length of disability for clinical malaria	3 days (1 – 7 days)	Assumption
	Length of disability for severe malaria	7 days (3 – 10 days)	Assumption
	Length of disability for anaemia due to clinical malaria	1 month $(0.5 - 2 \text{ months})$	Assumption
	Length of disability for anaemia due to severe malaria	3 months $(1 - 6 \text{ months})$	Assumption
	Disability weight for clinical malaria	0.051 (0.032 - 0.074)	[31]
	Disability weight for severe malaria	0.133 (0.088 - 0.190)	[31]
	Disability weight for moderate anaemia due to vivax malaria	0.052 (0.034 - 0.076)	[31]
	Disability weight for severe anaemia due to severe malaria or haemolysis	0.149 (0.101 – 0.209)	[31]
483			
484			
485			
486			
487			
488			
489			
490			
491			
492			
493			
494			
495			
496			
497			
498			
499			
500			
501			
502			
503			

Appendix 2. One-way sensitivity analysis of the impact of changing the base case parameter value to low and
 high values on the incremental cost-effectiveness ratios (ICERs) for Scenarios 3 (high primaquine adherence) and
 4 (low primaquine adherence) as compared to the baseline scenario for peri-urban Manaus, São Gabriel da
 Cachoeira, and Itaituba. See Tables 2 & 3 and Appendix 1 for the ranges used for this analysis.



517 Appendix 3. Cost-effectiveness planes showing the incremental costs and disability-adjusted life years (DALYs) 518 averted from 10,000 iterations in the probabilistic sensitivity analysis. Results are for Scenario 1 (tafenoquine for 519 adults, primaquine adherence 66.7%), Scenario 2 (tafenoquine for all, primaquine adherence 66.7%), Scenario 3 520 (tafenoquine for adults, high primaquine adherence of 90%), and Scenario 4 (tafenoquine for adults, low 521 primaquine adherence of 30%) compared to baseline (7 day low-dose primaquine (0.5 mg/kg), adherence set at 522 comparison scenario) overall for Brazil. The base case analysis results are designated by a black triangle in each 523 panel.



538	Appendix 4. Mean and 95% credible intervals from the probabilistic sensitivity analysis for disability-adjusted
F 2 0	life many (DALVe) exampled in energy and in energy and in energy and a first offertime and ration (ICERs)

Scenario	Incremental Costs	DALYs averted	ICER
1	11,863,099 (6,578,704, 18,409,257)	12,338 (7,639, 18,245)	1011 (480, 1,837)
2	7,619,267 (1,142,585, 14,633,037)	16,669 (10,127, 25,014)	483 (69, 1,052)
3	16,173,313 (11,640,655, 22,377,458)	8,682 (5,469, 12,802)	1954 (1104, 3,272)
4	2,765,773 (-4,867,346, 10,270,936)	20,120 (12,049, 30,663)	146 (-255, 589)
10			
1			
12			
13			
14			
15			
16			
17			
10			
ю 10			
19			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
50			
51			
52			
53			
4			

Appendix 5. Cost-effectiveness planes showing the incremental costs and disability-adjusted life years (DALYs)
 averted from 10,000 iterations in the probabilistic sensitivity analysis. All scenarios are compared to the baseline
 scenario for three municipalities. The base case analysis results are designated by a black triangle in each panel.



582 Appendix 6. Cost-effectiveness acceptability curves for each tafenoquine scenario in three municipalities
 583 compared to the baseline scenario. The black vertical line represents the willingness-to-pay threshold
 584 (USD\$7,800).

